Skyepharma plc, of London, said partner Mundipharma International Corp. Ltd., of Singapore, received confirmation that its marketing authorization application for a breath-actuated version of flutiform was accepted for review in Europe. Mundipharma is seeking approval for treating asthma in adults and adolescents where the use of a combination product (inhaled corticosteroid/long-acting beta2 agonist) is appropriate.